var data={"title":"Pegfilgrastim: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegfilgrastim: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6731?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegfilgrastim-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegfilgrastim: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pegfilgrastim-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegfilgrastim: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206840\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neulasta;</li>\n      <li>Neulasta Onpro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855049\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Neulasta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206855\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Colony Stimulating Factor;</li>\n      <li>\n        Hematopoietic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206842\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-induced neutropenia:</b> SubQ: 6 mg once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy; <b>Note:</b> Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic radiation injury syndrome (acute):</b> SubQ: 6 mg once weekly for 2 doses. Obtain a baseline CBC prior to administration, but do not delay pegfilgrastim use if a CBC is not readily obtainable. Administer the first dose as soon as possible after suspected or confirmed radiation exposure greater than 2 gray (Gy). Administer the second dose 1 week after the first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206850\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pegfilgrastim-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegfilgrastim: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-induced neutropenia:</b> <b>Note:</b> Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &lt;45 kg: SubQ: Administer once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy (dose and volume are based on patient weight). Maximum dose: 6 mg (Andre 2007; Borinstein 2009). <b>Note:</b> The prefilled syringe is not designed to allow for direct administration of doses less than 6 mg (0.6 mL). Due to the potential for dosing errors, the manufacturer does not recommend direct administration of doses less than 6 mg (0.6 mL); use caution to avoid dosing errors.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &lt;10 kg: 0.1 <b>mg/kg</b> (0.01 <b>mL/kg</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients 10 to 20 kg: 1.5 <b>mg</b> (0.15 <b>mL</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients 21 to 30 kg: 2.5 <b>mg</b> (0.25 <b>mL</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients 31 to 44 kg: 4 <b>mg</b> (0.4 <b>mL</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &ge;45 kg: SubQ: 6 mg once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic radiation injury syndrome (acute):</b> Obtain a baseline CBC prior to administration, but do not delay pegfilgrastim use if a CBC is not readily obtainable. Administer the first dose as soon as possible after suspected or confirmed radiation exposure greater than 2 gray (Gy). Administer the second dose 1 week after the first dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &lt;45 kg: SubQ: Administer 2 doses of pegfilgrastim one week apart (dose and volume are based on patient weight). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &lt;10 kg: 0.1 <b>mg/kg</b> (0.01 <b>mL/kg</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients 10 to 20 kg: 1.5 <b>mg</b> (0.15 <b>mL</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients 21 to 30 kg: 2.5 <b>mg</b> (0.25 <b>mL</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients 31 to 44 kg: 4 <b>mg</b> (0.4 <b>mL</b> volume)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &ge;45 kg: SubQ: 6 mg once weekly for 2 doses (the second dose should be administered 1 week after the first dose).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206843\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1628163\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22151364\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206826\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Prefilled Syringe Kit, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neulasta Onpro: 6 mg/0.6 mL (0.6 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neulasta: 6 mg/0.6 mL (0.6 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206813\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206829\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer subcutaneously. Do not use 6 mg fixed dose in infants, children, or adolescents &lt;45 kg (Smith 2006). Pegfilgrastim is available in prefilled syringes for manual subcutaneous administration or as a kit for use with the On-body injector. <b>Direct</b> administration of doses &lt;6 mg using the prefilled syringe is not recommended by the manufacturer (it does not have graduation marks necessary for accurate measurement of doses other than 6 mg); use caution to avoid dosing errors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Manual subcutaneous administration:</i> Administer to outer upper arms, abdomen (except within 2 inches of navel), front middle thigh, or upper outer buttocks. Allow prefilled syringe to reach room temperature for at least 30 minutes prior to injection. Engage/activate needle guard following use to prevent accidental needlesticks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>On-body injector:</i> A health care provider must fill the On-body injector (OBI) prior to applying to the patient&rsquo;s skin. Apply to intact, nonirritated skin on the back of the arm or abdomen (only use the back of the arm if caregiver is available to monitor OBI injection status). The OBI system will deliver pegfilgrastim over ~45 minutes approximately 27 hours after application. The OBI delivery system may be applied on the same day as chemotherapy administration as long as pegfilgrastim is delivered at least 24 hours after chemotherapy is administered. Keep the OBI dry for ~3 hours before dose delivery. Provide patient training and instruct patients to notify health care provider immediately if OBI malfunctions or did not perform as intended. A missed dose may occur if the OBI fails or leaks; if a dose is missed, administer a new dose by manual subcutaneous injection as soon as possible after discovery of missed dose. Do not expose the OBI to oxygen-rich environments (eg, hyperbaric chambers), MRI, x-ray (including airport x-ray), CT-scan, or ultrasound (may damage injector system). Keep the OBI at least 4 inches away from electrical equipment, including cell phones, cordless phones, microwaves, and other common appliances (injector may not work properly). The OBI is not recommended for use in patients with acute hematopoietic radiation injury syndrome. The OBI has not been studied in pediatric patients. Refer to prescribing information for further details.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The prefilled syringe provided in the OBI kit contains overfill to compensate for loss during delivery; do not use for manual subcutaneous injection (will result in higher than recommended dose). Do not use prefilled syringe intended for manual injection to fill the OBI; may result in lower than intended dose. The OBI is only for use with pegfilgrastim; do not use to deliver other medications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206828\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic radiation injury syndrome (acute):</b> To increase survival in patients acutely exposed to myelosuppressive doses of radiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-induced neutropenia:</b> To decrease the incidence of infection (as manifested by febrile neutropenia), in patients with nonmyeloid malignancies receiving myelosuppressive cancer chemotherapy associated with a clinically significant incidence of febrile neutropenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitation of use: Pegfilgrastim is not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2839880\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Neulasta may be confused with Lunesta, Neumega, Neupogen, Nuedexta </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206818\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Ostealgia (31%), limb pain (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Acute respiratory distress syndrome (ARDS), alopecia, anaphylaxis, antibody development, arthralgia, back pain, bruising at injection site, capillary leak syndrome, chest pain, constipation, diarrhea, erythema, fatigue, fever, flushing, glomerulonephritis, headache, hypersensitivity angiitis, hypertonia, increased serum alkaline phosphatase, increased uric acid, influenza, injection site reaction, leukocytosis, musculoskeletal pain, myalgia, neck pain, pain, pain at injection site, periorbital edema, peripheral edema, polyarthralgia, polymyalgia rheumatica, rhinitis, severe sickle cell crisis, skeletal pain, splenic rupture, splenomegaly, Sweet syndrome, urticaria, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206832\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (serious allergic reaction) to pegfilgrastim, filgrastim, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to <i>E. coli</i>-derived proteins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206816\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Capillary leak syndrome: Capillary leak syndrome (CLS), characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration, may occur in patients receiving human granulocyte colony-stimulating factors (G-CSF), including pegfilgrastim. CLS episodes vary in frequency and severity. If CLS develops, monitor closely and manage symptomatically (may require intensive care). CLS may be life-threatening if treatment is delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity, including serious allergic reactions or anaphylaxis may occur, usually with the initial dose; may recur within days after discontinuation of initial antiallergic treatment. Permanently discontinue for severe reactions. Do not administer in patients with a history of serious allergic reaction to pegfilgrastim or filgrastim. Skin rash, urticaria, generalized erythema, and flushing have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Glomerulonephritis has occurred, and generally resolved after pegfilgrastim dose reduction or discontinuation. Diagnosis was made by the presence of azotemia, microscopic and macroscopic hematuria, proteinuria, and renal biopsy. Evaluate if glomerulonephritis is suspected; if felt due to pegfilgrastim, consider dose reduction or therapy interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Leukocytosis (WBC &ge;100,000/mm<sup>3</sup>) has been reported in patients receiving pegfilgrastim. Monitor complete blood counts during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory distress syndrome: Acute respiratory distress syndrome (ARDS) has been reported with use; evaluate patients with pulmonary symptoms such as fever, pulmonary infiltrates, or respiratory distress for ARDS. Discontinue pegfilgrastim if ARDS occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Splenic rupture: Rare cases of splenic rupture have been reported (some fatal); patients must be instructed to report left upper abdominal pain or shoulder pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: May precipitate sickle cell crises in patients with sickle cell disorders (severe and sometimes fatal sickle cell crises have occurred with filgrastim).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytotoxic chemotherapy: Do not use pegfilgrastim in the period 14 days before to 24 hours after administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy. Safety and efficacy have not been established with dose-dense chemotherapy regimens (Smith 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly patients: The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update recommend that prophylactic colony-stimulating factors be used in patients &ge;65 years with diffuse aggressive lymphoma treated with curative chemotherapy (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), especially if patients have comorbid conditions (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric patients: The 6 mg fixed dose should not be used in infants, children, and adolescents weighing &lt;45 kg. Colony-stimulating factor (CSF) use in pediatric patients is typically directed by clinical pediatric protocols. The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update states that CSFs may be reasonable as primary prophylaxis in pediatric patients when chemotherapy regimens with a high likelihood of febrile neutropenia are employed. Likewise, secondary CSF prophylaxis should be limited to high-risk patients. In pediatric cancers in which dose-intense chemotherapy (with a survival benefit) is used, CSFs should be given to facilitate chemotherapy administration. CSFs should not be used in the pediatric population for non-relapsed acute lymphoblastic or myeloid leukemia when no infection is present (Smith 2015). The On-body injector has not been studied for use in pediatrics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stem cell mobilization: Not indicated for peripheral blood progenitor cell (PBPC) mobilization for hematopoietic stem cell transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acrylic: Some products may contain acrylic adhesive; patients sensitive to acrylic adhesives may experience a significant reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging (needle cover) contains latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; On-body injector: The On-body injector (OBI) is not recommended for use in patients with acute hematopoietic radiation injury syndrome. The OBI contains an acrylic adhesive; may result in a significant reaction in patients who react to acrylic adhesives. A health care provider must fill the OBI prior to applying to the patient's skin. The OBI delivery system may be applied on the same day as chemotherapy administration as long as pegfilgrastim is delivered no less than 24 hours after chemotherapy is administered. The prefilled syringe provided in the OBI kit contains overfill to compensate for loss during delivery; do not use for manual subcutaneous injection (will result in higher than recommended dose). Do not use prefilled syringe intended for manual injection to fill the OBI; may result in lower than intended dose. The OBI is only for use with pegfilgrastim; do not use to deliver other medications. Do not expose the OBI to oxygen-rich environments (eg, hyperbaric chambers); MRI; x-ray (including airport x-ray); CT scan; or ultrasound (may damage injector system). Keep the OBI at least 4 inches away from electrical equipment, including cell phones, cordless phones, microwaves, and other common appliances (injector may not work properly). Missed or partial doses have been reported; the risk for neutropenia, neutropenic fever, and/or infection is increased if a dose is not correctly delivered. Provide patient training and instruct patients to notify health care provider immediately if OBI malfunctions or did not perform as intended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Colony-stimulating factors may be considered in cancer patients with febrile neutropenia who are at high risk for infection-associated complications or who have prognostic factors indicative of a poor clinical outcome (eg, prolonged and severe neutropenia, age &gt;65 years, hypotension, pneumonia, sepsis syndrome, presence of invasive fungal infection, uncontrolled primary disease, hospitalization at the time of fever development) (Freifeld 2011; Smith 2006). Colony-stimulating factors should not be routinely used for patients with neutropenia who are afebrile. Dose-dense regimens that require colony-stimulating factors should only be used within the context of a clinical trial or if supported by convincing evidence. The safety/efficacy of pegfilgrastim in the setting of dose-dense therapy has not been fully established (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor growth factor: The granulocyte-colony stimulating factor (G-CSF) receptor through which pegfilgrastim (and filgrastim) work has been located on tumor cell lines. May potentially act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia (pegfilgrastim is not approved for myeloid malignancies).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299830\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206820\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10154&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belotecan: Granulocyte Colony-Stimulating Factors may enhance the neutropenic effect of Belotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Pegfilgrastim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Granulocyte Colony-Stimulating Factors may enhance the myelosuppressive effect of Topotecan. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206822\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206834\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women who are exposed to Neulasta during pregnancy are encouraged to enroll in the Amgen Pregnancy Surveillance Program (800-772-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617528\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pegfilgrastim is present in breast milk. The manufacturer recommends that caution be exercised when administering pegfilgrastim to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206824\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chemotherapy-induced neutropenia: Complete blood count (with differential) and platelet count should be obtained prior to chemotherapy and as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematopoietic radiation injury syndrome: CBC at baseline (do not delay administration if CBC not readily available); estimate absorbed radiation dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evaluate fever, pulmonary infiltrates, and respiratory distress; evaluate for left upper abdominal pain, shoulder tip pain, or splenomegaly. Monitor for signs/symptoms of glomerulonephritis (azotemia, hematuria, proteinuria) and capillary leak syndrome (hypotension, hypoalbuminemia, edema and hemoconcentration). Monitor for sickle cell crisis (in patients with sickle cell anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">On-body injector: Monitor for evidence of device malfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206815\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pegfilgrastim stimulates the production, maturation, and activation of neutrophils and activates neutrophils to increase both their migration and cytotoxicity. Pegfilgrastim has a prolonged duration of effect relative to filgrastim and a reduced renal clearance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206831\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: SubQ: Pediatrics (100 mcg/kg dose): 0 to 5 years: 30.1 &plusmn; 38.2 hours; 6 to 11 years: 20.2 &plusmn; 11.3 hours; 12 years and older: 21.2 &plusmn; 16 hours; Adults: 15 to 80 hours. Pharmacokinetics (in adults) were comparable between manual subcutaneous injection and the On-body injector system.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily through binding to neutrophils</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206833\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe Kit</b> (Neulasta Onpro Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.6 mL (0.6 mL): $7,477.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Neulasta Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.6 mL (0.6 mL): $7,477.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206835\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>G-Lasta (JP);</li>\n      <li>Neulasta (AT, AU, BB, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IS, IT, KR, LT, LU, LV, MT, NL, NO, PL, PT, RO, RU, SE, SI, SK, TR, TW);</li>\n      <li>Neulastim (AE, AR, BR, CL, CO, CR, DO, EC, GT, HK, ID, IL, IN, JO, KW, LB, MY, NI, NZ, PA, PE, PY, QA, SA, SG, SV, TH, UY, VN);</li>\n      <li>Neulastyl (PH);</li>\n      <li>Neulastym (UA);</li>\n      <li>Neupopeg (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IT, MT, NL, NO, PT, RU, SE, SK, TR);</li>\n      <li>Peg-Grafeel (VN);</li>\n      <li>Pegfilgrast (BD);</li>\n      <li>Peglasta (MY, PH, SG, TH);</li>\n      <li>Pegneufil (BD);</li>\n      <li>Pegstim (PH);</li>\n      <li>Ristempa (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Andre N, Kababri ME, Bertrand P, et al, &ldquo;Safety and Efficacy of Pegfilgrastim in Children With Cancer Receiving Myelosuppressive Chemotherapy,&rdquo; <i>Anticancer Drugs</i>, 2007, 18(3):277-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/17264759/pubmed\" target=\"_blank\" id=\"17264759\">17264759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Becker PS, Wagle M, Matous S, et al, &quot;Spontaneous Splenic Rupture Following Administration of Granulocyte Colony-Stimulating Factor (G-CSF): Occurrence in an Allogeneic Donor of Peripheral Blood Stem Cells,&quot; <i>Biol Blood Marrow Transplant</i>, 1997, 3(1):45-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/9209740/pubmed\" target=\"_blank\" id=\"9209740\">9209740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borinstein SC, Pollard J, Winter L, et al. Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. <i>Pediatr Blood Cancer</i>. 2009; 53(3):375-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/19484756/pubmed\" target=\"_blank\" id=\"19484756\">19484756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donadieu J, Beaupain B, Rety-Jacob F, et al, &quot;Respiratory Distress and Sudden Death of a Patient With GSDIb Chronic Neutropenia: Possible Role of Pegfilgrastim,&quot; <i>Haematologica</i>, 2009, 94(8):1175-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/19644144/pubmed\" target=\"_blank\" id=\"19644144\">19644144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):427-431.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/21205990/pubmed\" target=\"_blank\" id=\"21205990\">21205990</a>]</span><span class=\"doi\">10.1093/cid/ciq147</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fox E, Widemann BC, Hawkins DS, et al. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. <i>Clin Cancer Res</i>. 2009;15(23):7361-7367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/19920107/pubmed\" target=\"_blank\" id=\"19920107\">19920107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes FA, O&rsquo;Shaughnessy JA, Vukelja S, et al, &ldquo;Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once Per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2002, 20(3): 727-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/11821454/pubmed\" target=\"_blank\" id=\"11821454\">11821454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaidar-Person O, Moskovitz M, Charas T, et al, &quot;Pegfilgrastim Overdose: Case Report and Review of the Literature,&quot; <i>Med Oncol</i>, 2011, 28(Suppl 1):S697-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/21107754/pubmed\" target=\"_blank\" id=\"21107754\">21107754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirshner JJ, Heckler CE, Janelsins MC, et al. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. <i>J Clin Oncol</i>. 2012;30(16):1974-1979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/22508813/pubmed\" target=\"_blank\" id=\"22508813\">22508813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuendgen A, Fenk R, Bruns I, et al, &ldquo;Splenic Rupture Following Administration of Pegfilgrastim in a Patient With Multiple Myeloma Undergoing Autologous Peripheral Stem Cell Transplantation,&rdquo; <i>Bone Marrow Transplant</i>, 2006, 38(1):69-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/16715114/pubmed\" target=\"_blank\" id=\"16715114\">16715114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neulasta (pegfilgrastim) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riu G, Estefanell A, Nomdedeu M, et al, &quot;Overdose of Pegfilgrastim: Case Report,&quot; <i>Int J Clin Pharm</i>, 2012, 34(5):690-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/22821554/pubmed\" target=\"_blank\" id=\"22821554\">22821554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2015;33(28):3199-3212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/26169616/pubmed\" target=\"_blank\" id=\"26169616\">26169616</a>]</span><span class=\"doi\">10.1200/JCO.2015.62.3488</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. <i>J Clin Oncol</i>. 2006;24(19):3187-3205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/16682719/pubmed\" target=\"_blank\" id=\"16682719\">16682719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spunt SL, Irving H, Frost J, et al. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. <i>J Clin Oncol</i>. 2010;28(8):1329-1336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegfilgrastim-drug-information/abstract-text/20142595/pubmed\" target=\"_blank\" id=\"20142595\">20142595</a>]</span><span class=\"doi\">10.1200/JCO.2009.24.8872</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolff AC, Jones RJ, Davidson NE, et al, &ldquo;Myeloid Toxicity in Breast Cancer in Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support,&rdquo; <i>J Clin Oncol</i>, 2006, 24(15):2392-4.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10154 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206840\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855049\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F206855\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206842\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F206850\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F206843\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F1628163\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22151364\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206826\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206813\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F206829\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206828\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2839880\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206818\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206832\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206816\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299830\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206820\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206822\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206834\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617528\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F206824\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206815\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206831\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F206833\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206835\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10154|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegfilgrastim-patient-drug-information\" class=\"drug drug_patient\">Pegfilgrastim: Patient drug information</a></li><li><a href=\"topic.htm?path=pegfilgrastim-pediatric-drug-information\" class=\"drug drug_pediatric\">Pegfilgrastim: Pediatric drug information</a></li></ul></div></div>","javascript":null}